It is reported that, according to the announcement of the third batch of Beijing International Science and Technology Cooperation Base designations by the Beijing Municipal Science and Technology Commission, NORTHLAND has been designated as the “Beijing International Science and Technology Cooperation Base for Recombinant Innovative Drugs.”

The Beijing International Science and Technology Cooperation Base was launched in 2011 with the aim of recognizing a group of international science and technology cooperation bases, guiding enterprises and research institutions to enhance their independent innovation capabilities through international scientific and technological cooperation, and fostering a number of outstanding international science and technology cooperation projects. NORTHLAND has successfully carried out two-way technological cooperation with foreign pharmaceutical and R&D companies, exporting and importing technologies related to new drug development, thereby boosting the company’s new drug R&D efforts. After submitting an application and undergoing a defense presentation, expert reviewers concluded that NORTHLAND possesses the conditions and capabilities to independently engage in international science and technology cooperation and fully meets the eligibility criteria for the Beijing International Science and Technology Cooperation Base.

Having been recognized as a Beijing International Science and Technology Cooperation Base for Recombinant New Drugs, the company, under the guidance and support of the Municipal Science and Technology Commission, will further expand its international collaborations, fully leveraging both domestic and overseas advantageous resources. We will actively engage in new drug R&D, international technology transfer, and the recruitment of high-caliber talent, thereby contributing to Beijing’s transformation into an innovation hub with global influence.